Tevogen (TVGN) reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1B in revenue in its launch year and a cumulative five-year estimate of between $10B and $14B. The forecast reflects the company’s drug development model. “With our intellectual property secured, Tevogen continues to build its U.S.-based cell therapy manufacturing capabilities, and I look forward to updating our shareholders on our forecasts and internal assets valuation,” commented Ryan Saadi, founder and CEO of Tevogen.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVGN:
- Tevogen Bio Signs Agreement with CD 8 Technology
- Tevogen says Databricks commissioned to accelerate PredicTcell development
- Tevogen announces Tevogen Generics following Trump’s tariff-related statements
- Tevogen Bio Holdings Delays Annual Report Filing
- Tevogen announces new patent filed for T cell vaccine